TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tai Chi or Hydrotherapy for People With Osteoarthritis of the Hip(s) or Knee(s)
Brief Summary: The aim of this study is to determine, in the framework of a randomized controlled clinical trial, whether Tai Chi can affect measurable improvements in self-reported outcomes such as pain, physical function and psychological well-being in people with osteoarthritis (OA) mainly affecting the hips or knees. The effectiveness of Tai Chi will be compared with both a non-intervention control group as well as with a formal exercise program, hydrotherapy. Hydrotherapy has long been considered an effective intervention for people with chronic OA although scientific evidence is weak at present. The main study hypotheses are that Tai Chi or hydrotherapy can significantly decrease pain and physical limitations; improve health-related quality of life; and promote psychological well being in patients with OA of the hip(s) or knee(s); and that Tai Chi and hydrotherapy are of equal efficacy.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral graded activity | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise therapy | Intervention Type: BEHAVIORAL; Name: Behavioral graded activity; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Exercise therapy; Assigned to Arm(s): B
B: Intervention Type: BEHAVIORAL; Name: Tai Chi classes; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Hydrotherapy classes; Assigned to Arm(s): N/A
C: Arm Label: yoga intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Hatha yoga | Arm Label: wait list control; Type: OTHER; Interventions: Behavioral: Hatha Yoga | Intervention Type: BEHAVIORAL; Name: Hatha yoga; Assigned to Arm(s): yoga intervention | Intervention Type: BEHAVIORAL; Name: Hatha Yoga; Assigned to Arm(s): wait list control
D: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: Tai Chi versus Attention Control | Arm Label: Wellness Education and Stretching; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Tai Chi versus Attention Control | Intervention Type: BEHAVIORAL; Name: Tai Chi versus Attention Control; Assigned to Arm(s): Tai Chi, Wellness Education and Stretching

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Persistent Urinary Incontinence in Children
Brief Summary: The purpose of this study is to determine whether surgical section of the filum terminale in children, when added to standard medical therapy, will result in a reliable and clinically-significant improvement in two main markers of incontinence within/at 12 months after treatment.


Options:
A: Arm Label: Surgical; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Medical Treatment | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Surgical | Intervention Type: PROCEDURE; Name: Medical Treatment; Assigned to Arm(s): Medical Treatment
B: Intervention Type: DEVICE; Name: Nerve stimulator; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mictonetten 5 mg, coated tablet | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mictonetten 5 mg, coated tablet; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Placebo Children; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Urotherapy | Arm Label: Solifenacin Succinate Suspension Children; Type: EXPERIMENTAL; Interventions: Drug: Solifenacin Succinate Suspension, Behavioral: Urotherapy | Arm Label: Placebo Adolescents; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Urotherapy | Arm Label: Solifenacin Succinate Suspension Adolescents; Type: PLACEBO_COMPARATOR; Interventions: Drug: Solifenacin Succinate Suspension, Behavioral: Urotherapy | Intervention Type: DRUG; Name: Solifenacin Succinate Suspension; Assigned to Arm(s): Solifenacin Succinate Suspension Adolescents, Solifenacin Succinate Suspension Children | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Adolescents, Placebo Children | Intervention Type: BEHAVIORAL; Name: Urotherapy; Assigned to Arm(s): Placebo Adolescents, Placebo Children, Solifenacin Succinate Suspension Adolescents, Solifenacin Succinate Suspension Children

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma in a Decentralized Patient Population: Is Traditional Disease Management Enough? A Randomized, Controlled Trial Comparing Traditional Care to Two Systems of Disease Management for a Decentralized Population of Patients in South Texas
Brief Summary: This is a health services demonstration project that evaluates three methods of health care delivery for the management of individuals with symptoms of asthma. This study will evaluate the impact of a telephonic asthma disease management process, with and without a home intervention program, on preventing asthma-related morbidity through patient/family asthma education.

The investigators' central thesis is that comprehensive clinical disease management protocols for the management of asthma will improve clinical outcomes; reduce fiscal resource consumption; and improve both patient satisfaction and patient quality of life. Additionally, individualized, in-home patient education and environmental assessment, when added to the telephonic protocol, will further improve these measures. However, incremental improvement will vary according to the population's access to care.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
B: Arm Label: Integrative Medicine; Type: EXPERIMENTAL; Interventions: Behavioral: Integrative Medicine | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrative Medicine; Assigned to Arm(s): Integrative Medicine
C: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Asthma in a Decentralized Patient Population: Is Traditional Disease Management Enough? A Randomized, Controlled Trial Comparing Traditional Care to Two Systems of Disease Management for a Decentralized Population of Patients in South Texas
Brief Summary: This is a health services demonstration project that evaluates three methods of health care delivery for the management of individuals with symptoms of asthma. This study will evaluate the impact of a telephonic asthma disease management process, with and without a home intervention program, on preventing asthma-related morbidity through patient/family asthma education.

The investigators' central thesis is that comprehensive clinical disease management protocols for the management of asthma will improve clinical outcomes; reduce fiscal resource consumption; and improve both patient satisfaction and patient quality of life. Additionally, individualized, in-home patient education and environmental assessment, when added to the telephonic protocol, will further improve these measures. However, incremental improvement will vary according to the population's access to care.


Options:
A: Arm Label: Control Subjects; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention Subjects; Type: EXPERIMENTAL; Interventions: Behavioral: Intervention Subjects | Intervention Type: BEHAVIORAL; Name: Intervention Subjects; Assigned to Arm(s): Intervention Subjects
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Asthma Communication Education | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Asthma Education | Intervention Type: BEHAVIORAL; Name: Asthma Communication Education; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Standard Asthma Education; Assigned to Arm(s): 2
C: Intervention Type: BEHAVIORAL; Name: Disease Management; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Disease Management + Educational Home Visits; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Using Parent Mentors to Improve Asthma Care for Urban Minority Children; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Ultrafiltration Versus IV Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Clinical Trial
Brief Summary: The purpose of this study is to compare patients who are suffering from heart failure and who are fluid overloaded to determine if ultrafiltration (UF) can remove more of the extra fluid as measured by weight loss while in the hospital and improve the patient's breathing.


Options:
A: Intervention Type: DRUG; Name: Beta-blockers including Carvedilol; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: ACE inhibitors; Assigned to Arm(s): N/A
B: Arm Label: Serelaxin (RLX030); Type: EXPERIMENTAL; Interventions: Drug: RLX030 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RLX030; Assigned to Arm(s): Serelaxin (RLX030) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ultrafiltration Group; Type: ACTIVE_COMPARATOR; Interventions: Device: CHIARA-System | Arm Label: Control group (Usual care IV diuretics); Type: OTHER; Interventions: Other: Usual care IV diuretics | Intervention Type: DEVICE; Name: CHIARA-System; Assigned to Arm(s): Ultrafiltration Group | Intervention Type: OTHER; Name: Usual care IV diuretics; Assigned to Arm(s): Control group (Usual care IV diuretics)
D: Intervention Type: DEVICE; Name: Aquadex system; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: IV diuretic; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial
Brief Summary: Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. Studies of the efficacy of intrarectal quinine in the treatment of cerebral malaria are limited. The study aims to establish the efficacy of intrarectal quinine in the treatment of childhood cerebral malaria.


Options:
A: Arm Label: Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chloroquine | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): Treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Control
B: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial
Brief Summary: Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. Studies of the efficacy of intrarectal quinine in the treatment of cerebral malaria are limited. The study aims to establish the efficacy of intrarectal quinine in the treatment of childhood cerebral malaria.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine /pyrimethamine plus amodiaquine; Assigned to Arm(s): N/A
B: Arm Label: SP and amodiaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: SP plus amodiaquine | Arm Label: SP placebo plus amodiaquine placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: SP placebo plus amodiaquine placebo | Intervention Type: DRUG; Name: SP plus amodiaquine; Assigned to Arm(s): SP and amodiaquine | Intervention Type: DRUG; Name: SP placebo plus amodiaquine placebo; Assigned to Arm(s): SP placebo plus amodiaquine placebo
C: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial
Brief Summary: Cerebral malaria is the most lethal complication of P.falciparum infection with a mortality rate between 5 and 40%. Intravenous quinine remains the recommended treatment for cerebral malaria. However its administration is often not feasible due to lack of simple equipment or trained staff. When referral is not possible, a viable alternative is needed. The intrarectal route is of interest in children since it is painless and simple. Studies of the efficacy of intrarectal quinine in the treatment of cerebral malaria are limited. The study aims to establish the efficacy of intrarectal quinine in the treatment of childhood cerebral malaria.


Options:
A: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Intrarectal quinine; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Intermittent preventive treatment (SP and amodiaquine) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Intermittent preventive treatment (SP and amodiaquine); Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Seasonal IPT in children - Sulfadoxine-pyrimethamine | Intervention Type: DRUG; Name: Seasonal IPT in children - Sulfadoxine-pyrimethamine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients
Brief Summary: This is a randomized clinical trial study to test the efficacy and safety of amitriptyline in the treatment of patients newly diagnosed with painful bladder syndrome (PBS). PBS is defined by symptoms--frequent urination day and night and increasing pain as the bladder fills--according to the International Continence Society. The syndrome includes interstitial cystitis (IC), which has been estimated to affect as many as 700,000 people, mostly women. Estimates for PBS vary widely, but as many as 10 million people may suffer from this condition. Although amitriptyline is a Food and Drug Administration (FDA)-approved medication used for depression, the way it works makes it useful for treating the pain of fibromyalgia, multiple sclerosis, and other chronic pain syndromes. Prior small studies in interstitial cystitis (IC) suggested the drug may be a wise choice for this syndrome as well, because it blocks nerve signals that trigger pain and may also decrease muscle spasms in the bladder, helping to relieve the symptoms of pain and frequent urination.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amitriptyline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran hydrochloride | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran hydrochloride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients
Brief Summary: This is a randomized clinical trial study to test the efficacy and safety of amitriptyline in the treatment of patients newly diagnosed with painful bladder syndrome (PBS). PBS is defined by symptoms--frequent urination day and night and increasing pain as the bladder fills--according to the International Continence Society. The syndrome includes interstitial cystitis (IC), which has been estimated to affect as many as 700,000 people, mostly women. Estimates for PBS vary widely, but as many as 10 million people may suffer from this condition. Although amitriptyline is a Food and Drug Administration (FDA)-approved medication used for depression, the way it works makes it useful for treating the pain of fibromyalgia, multiple sclerosis, and other chronic pain syndromes. Prior small studies in interstitial cystitis (IC) suggested the drug may be a wise choice for this syndrome as well, because it blocks nerve signals that trigger pain and may also decrease muscle spasms in the bladder, helping to relieve the symptoms of pain and frequent urination.


Options:
A: Arm Label: Botulinum toxin A; Type: EXPERIMENTAL; Interventions: Drug: Botulinum toxin A | Arm Label: Control arm-Normal saline instillation; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline instillation | Intervention Type: DRUG; Name: Botulinum toxin A; Assigned to Arm(s): Botulinum toxin A | Intervention Type: DRUG; Name: Normal saline instillation; Assigned to Arm(s): Control arm-Normal saline instillation
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amitriptyline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Group 1: Experimental; Type: ACTIVE_COMPARATOR; Interventions: Biological: Certolizumab pegol | Arm Label: Group 2: Placebo Comparator; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Group 1: Experimental | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2: Placebo Comparator
D: Arm Label: Bladder instillation WITH triamcinolone acetonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bladder instillation WITH triamcinolone acetonide | Arm Label: Bladder instillation WITHOUT triamcinolone acetonide; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bladder instillation WITHOUT triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITH triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITH triamcinolone acetonide | Intervention Type: DRUG; Name: Bladder instillation WITHOUT triamcinolone acetonide; Assigned to Arm(s): Bladder instillation WITHOUT triamcinolone acetonide

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Multicenter, Double-Blind, Placebo-Controlled, Two-Arm Parallel Group Trial of Rimonabant 20-mg od, for Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds), in Overweight Patients With Clustering Risk Factors
Brief Summary: The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as needed, in patients with abdominal obesity associated with current smoking and/or metabolic syndrome.


Options:
A: Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Rimonabant (SR141716); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Arm Label: NB16; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Behavioral: Ancillary therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Ancillary therapy | Intervention Type: DRUG; Name: Naltrexone SR 16 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB16 | Intervention Type: DRUG; Name: Naltrexone SR 32 mg/Bupropion SR 360 mg /day; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Ancillary therapy; Assigned to Arm(s): NB16, NB32, Placebo
D: Arm Label: NB32; Type: EXPERIMENTAL; Interventions: Drug: NB32, Behavioral: Weight Management Program | Arm Label: PBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: PBO, Behavioral: Weight Management Program | Intervention Type: DRUG; Name: NB32; Assigned to Arm(s): NB32 | Intervention Type: DRUG; Name: PBO; Assigned to Arm(s): PBO | Intervention Type: BEHAVIORAL; Name: Weight Management Program; Assigned to Arm(s): NB32, PBO

Answer: B